Last updated on May 2020

A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Brief description of study

The primary objective of this study is to compare MK-6482 to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior to everolimus with respect to PFS and OS.

Clinical Study Identifier: NCT04195750

Find a site near you

Start Over

Hattiesburg Clinic ( Site 1509)

Hattiesburg, MS United States
  Connect »

National Cancer Center ( Site 1204)

Gyeonggi-do, Korea, Republic of
  Connect »